Citations (15)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Paul Dent. (2013) The multi-hit hypothesis in basal-like breast cancer. Cancer Biology & Therapy 14:9, pages 778-779.
Read now
Read now
Articles from other publishers (14)
Aranka Brockmueller, Anjana Sajeev, Lenka Koklesova, Samson Mathews Samuel, Peter Kubatka, Dietrich Büsselberg, Ajaikumar B. Kunnumakkara & Mehdi Shakibaei. (2023) Resveratrol as sensitizer in colorectal cancer plasticity. Cancer and Metastasis Reviews.
Crossref
Crossref
Paola Villalobos Gutiérrez, José Muñoz Carrillo, Cuauhtémoc Sandoval Salazar, Juan Viveros Paredes & Oscar Gutiérrez Coronado. (2023) Functionalized Metal Nanoparticles in Cancer Therapy. Pharmaceutics 15:7, pages 1932.
Crossref
Crossref
Yanfei Liu, Shifeng Tian, Ben Yi, Zhiqiang Feng, Tianhao Chu, Jun Liu, Chunze Zhang, Shiwu Zhang & Yijia Wang. (2022) Platycodin D sensitizes KRAS-mutant colorectal cancer cells to cetuximab by inhibiting the PI3K/Akt signaling pathway. Frontiers in Oncology 12.
Crossref
Crossref
Marika Colombo, Mirko Marabese, Giulia Vargiu, Massimo Broggini & Elisa Caiola. (2020) Activity of Birinapant, a SMAC Mimetic Compound, Alone or in Combination in NSCLCs With Different Mutations. Frontiers in Oncology 10.
Crossref
Crossref
Yijia Wang, Wenhong Wang, Xiaojing Wu, Chunjun Li, Yaping Huang, Huiyan Zhou & Yu Cui. (2020) Resveratrol Sensitizes Colorectal Cancer Cells to Cetuximab by Connexin 43 Upregulation-Induced Akt Inhibition. Frontiers in Oncology 10.
Crossref
Crossref
Hidejiro Torigoe, Hiromasa Yamamoto, Masakiyo Sakaguchi, Chen Youyi, Kei Namba, Hiroki Sato, Kazuhiko Shien, Junichi Soh, Ken Suzawa, Shuta Tomida, Kazunori Tsukuda, Shinichiro Miyoshi & Shinichi Toyooka. (2018) Tumor-suppressive effect of LRIG1, a negative regulator of ErbB, in non-small cell lung cancer harboring mutant EGFR. Carcinogenesis 39:5, pages 719-727.
Crossref
Crossref
Ji Young YunByung-Hwa HyunSang Yoon NamYoung Won YunHu-Jang LeeBeom-Jun Lee. (2018) The effect of near-infrared fluorescence conjugation on the anti-cancer potential of cetuximab. Laboratory Animal Research 34:1, pages 30.
Crossref
Crossref
Jharna Datta, Senthilkumar Damodaran, Hannah Parks, Cristina Ocrainiciuc, Jharna Miya, Lianbo Yu, Elijah P. Gardner, Eric Samorodnitsky, Michele R. Wing, Darshna Bhatt, John Hays, Julie W. Reeser & Sameek Roychowdhury. (2017) Akt Activation Mediates Acquired Resistance to Fibroblast Growth Factor Receptor Inhibitor BGJ398. Molecular Cancer Therapeutics 16:4, pages 614-624.
Crossref
Crossref
MIYAKO TAKATA, HIROKI CHIKUMI, KEIJI MATSUNAMI, MASAHIRO KODANI, TOMOHIRO SAKAMOTO, KAZUHIRO HASHIMOTO, MASAKI NAKAMOTO, KENSAKU OKADA, TSUYOSHI KITAURA, SHINGO MATSUMOTO, JUN KURAI, AKIRA YAMASAKI, TADASHI IGISHI, NAOTO BURIOKA & EIJI SHIMIZU. (2015) A new rapid method for detecting epidermal growth factor receptor mutations in non-small cell lung cancer. Oncology Reports 33:3, pages 1040-1048.
Crossref
Crossref
Yichun Qian, Mantang Qiu, Qingquan Wu, Yanyan Tian, Yu Zhang, Ning Gu, Suyi Li, Lin Xu & Rong Yin. (2014) Enhanced cytotoxic activity of cetuximab in EGFR-positive lung cancer by conjugating with gold nanoparticles. Scientific Reports 4:1.
Crossref
Crossref
Kaito Nihira, Yasuhiro Miki, Shinya Iida, Sodai Narumi, Katsuhiko Ono, Erina Iwabuchi, Kazue Ise, Kazushige Mori, Mikiyoshi Saito, Masahito Ebina, Ikuro Sato, Makoto Maemondo, Hisafumi Yamada-Okabe, Takashi Kondo & Hironobu Sasano. (2014)
An activation of LC3A-mediated autophagy contributes to
de novo
and acquired resistance to EGFR tyrosine kinase inhibitors in lung adenocarcinoma
. The Journal of Pathology, pages n/a-n/a.
Crossref
Crossref
Jason E. Ekert, Kjell Johnson, Brandy Strake, Jose Pardinas, Stephen Jarantow, Robert Perkinson & David C. Colter. (2014) Three-Dimensional Lung Tumor Microenvironment Modulates Therapeutic Compound Responsiveness In Vitro ? Implication for Drug Development. PLoS ONE 9:3, pages e92248.
Crossref
Crossref
SHIZUKA ITO, TADASHI IGISHI, MIYAKO TAKATA, YASUTO UEDA, SHINGO MATSUMOTO, MASAHIRO KODANI, KENICHI TAKEDA, HIROKI IZUMI, TOMOHIRO SAKAMOTO, KOSUKE YAMAGUCHI, HARUHIKO MAKINO, HIROKAZU TOUGE, HIROKI CHIKUMI & EIJI SHIMIZU. (2014) Synergistic cell growth inhibition by the combination of amrubicin and Akt-suppressing agents in K-ras mutation-harboring lung adenocarcinoma cells: Implication of EGFR tyrosine kinase inhibitors. International Journal of Oncology 44:3, pages 685-692.
Crossref
Crossref
R Castoldi, V Ecker, L Wiehle, M Majety, R Busl-Schuller, M Asmussen, A Nopora, U Jucknischke, F Osl, S Kobold, W Scheuer, M Venturi, C Klein, G Niederfellner & C Sustmann. (2013) A novel bispecific EGFR/Met antibody blocks tumor-promoting phenotypic effects induced by resistance to EGFR inhibition and has potent antitumor activity. Oncogene 32:50, pages 5593-5601.
Crossref
Crossref